{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:41:55Z","timestamp":1760060515267,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Objective: Fabry disease (FD) is a rare, X-linked lysosomal storage disorder resulting from deficient \u03b1-galactosidase A activity, which can manifest as left ventricular hypertrophy (LVH). We aimed to assess the prevalence of FD in an unselected cohort of patients with unexplained LVH. Methods and results: We screened 202 unrelated adults with LVH using enzymatic assays for \u03b1-galactosidase A in dried blood spots. Patients with low activity underwent GLA gene sequencing. Echocardiographic parameters were evaluated according to ESC guidelines. FD was diagnosed in 4 women (2%), each carrying distinct pathogenic GLA mutations. All affected individuals showed normal or borderline enzyme activity. Cardiac, renal, or neurological symptoms were observed variably among patients. Echocardiographic findings revealed slightly lower wall thickness and preserved systolic function in FD patients compared to those without FD. Cascade genetic screening identified 16 additional family members with the same mutations. One patient (0.5%) was incidentally diagnosed with Gaucher disease based on syndromic features and enzymatic testing. Conclusions: FD was identified in 2% of patients with unexplained LVH, who were females. Enzyme-based screening followed by targeted genetic testing is a cost-effective strategy for FD detection. Early diagnosis is essential for prompt treatment and family counselling, underscoring the importance of routine FD screening in patients with LVH of unclear aetiology. Our findings support the use of targeted screening for Fabry disease in patients with LVH and systemic features, and highlight the potential to identify other lysosomal disorders in selected cases.<\/jats:p>","DOI":"10.3390\/medsci13030162","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:28:15Z","timestamp":1756715295000},"page":"162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Looking for Fabry, Finding More: LVH Screening Yields Unexpected Gaucher Diagnosis"],"prefix":"10.3390","volume":"13","author":[{"given":"Sylwia","family":"Szczepara","sequence":"first","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"Pacia","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Trojanowicz","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"Bielecka","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"},{"name":"Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Tworek","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"},{"name":"Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Sachajko","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"},{"name":"Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-4076","authenticated-orcid":false,"given":"Katarzyna","family":"Holcman","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"},{"name":"Department of Nuclear Medicine, St. John Paul II Hospital, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6101-2935","authenticated-orcid":false,"given":"Piotr","family":"Podolec","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Komar","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland"},{"name":"Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Fabry Disease. GeneReviews(\u00ae), University of Washington.","key":"ref_1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol. Genet. Metab."},{"doi-asserted-by":"crossref","unstructured":"Celi, A.B., Goldstein, J., Rosato-Siri, M.V., and Pinto, A. (2022). Role of Globotriaosylceramide in Physiology and Pathology. Front. Mol. Biosci., 9.","key":"ref_3","DOI":"10.3389\/fmolb.2022.813637"},{"doi-asserted-by":"crossref","unstructured":"Muntean, C., Starcea, I.M., Stoica, C., and Banescu, C. (2022). Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients with Fabry Disease. Front. Pediatr., 10.","key":"ref_4","DOI":"10.3389\/fped.2022.908657"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jgf2.76","article-title":"Fabry disease and its cardiac involvement","volume":"18","author":"Kubo","year":"2017","journal-title":"J. Gen. Fam. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and How to Diagnose Fabry Disease in Clinical Pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jmg-2022-108523","article-title":"Prevalence of Fabry disease-causing variants in the UK Biobank","volume":"60","author":"Gilchrist","year":"2023","journal-title":"J. Med. Genet."},{"doi-asserted-by":"crossref","unstructured":"Averbuch, T., White, J.A., and Fine, N.M. (2023). Anderson-Fabry disease cardiomyopathy: An update on epidemiology, diagnostic approach, management and monitoring strategies. Front. Cardiovasc. Med., 10.","key":"ref_9","DOI":"10.3389\/fcvm.2023.1152568"},{"doi-asserted-by":"crossref","unstructured":"Umer, M., and Kalra, D.K. (2022). Cardiac MRI in Fabry disease. Front. Cardiovasc. Med., 9.","key":"ref_10","DOI":"10.3389\/fcvm.2022.1075639"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.ijcard.2012.06.069","article-title":"Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy","volume":"167","author":"Terryn","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10554-023-02826-w","article-title":"Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis)","volume":"39","author":"Ekici","year":"2023","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3346\/jkms.2019.34.e63","article-title":"Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy","volume":"34","author":"Kim","year":"2019","journal-title":"J. Korean Med. Sci."},{"doi-asserted-by":"crossref","unstructured":"Leung, S.P., Dougherty, S., Zhang, X.Y., Kam, K.K.H., Chi, W.K., Chan, J.Y.S., Fung, E., Wong, J.K.T., Choi, P.C.L., and Chan, D.K.H. (2024). The Asian Fabry Cardiomyopathy High-Risk Screening Study 2 (ASIAN-FAME-2): Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy. J. Clin. Med., 13.","key":"ref_14","DOI":"10.3390\/jcm13133896"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry Disease in Male Patients with Late Onset Hypertrophic Cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An Atypical Variant of Fabry\u2019s Disease in Men with Left Ventricular Hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.15420\/aer.2013.2.1.36","article-title":"Mimics of Hypertrophic Cardiomyopathy\u2014Diagnostic Clues to Aid Early Identification of Phenocopies","volume":"2","author":"Sankaranarayanan","year":"2013","journal-title":"Arrhythmia Electrophysiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease","volume":"12","author":"Perry","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.revmed.2018.11.012","article-title":"La maladie de Gaucher: Quand y penser? [Gaucher disease: When to suspect it?]","volume":"40","author":"Nguyen","year":"2019","journal-title":"Rev. Med. Interne"},{"doi-asserted-by":"crossref","unstructured":"(1980). Report of the WHO\/ISFC task force on the definition and classification of cardiomyopathies. Br. Heart J., 44, 672\u2013673.","key":"ref_20","DOI":"10.1136\/hrt.44.6.672"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients with Hypertrophic Cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","article-title":"Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imaging","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: The European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1002\/ehf2.15065","article-title":"Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study","volume":"11","author":"Lin","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e14388","DOI":"10.1111\/eci.14388","article-title":"Imaging Predictors of Adverse Prognosis in Fabry Disease Cardiomyopathy: A Systematic Review and Meta-Analysis","volume":"55","author":"Stankowski","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e230154","DOI":"10.1148\/ryct.230154","article-title":"Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis","volume":"6","author":"Figliozzi","year":"2024","journal-title":"Radiol. Cardiothorac. Imaging"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/13\/3\/162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:36:54Z","timestamp":1760035014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/13\/3\/162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medsci13030162"],"URL":"https:\/\/doi.org\/10.3390\/medsci13030162","relation":{},"ISSN":["2076-3271"],"issn-type":[{"type":"electronic","value":"2076-3271"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}